Clinical Trial Documentation Essentials

Clinical trial documentation is more than an administrative task. It is the evidence that participant rights were protected, the protocol was followed, and the results reported can be trusted. Strong documentation also helps the trial team reconstruct decisions, respond to questions, and remain inspection-ready throughout the lifecycle of the study.

Why documentation discipline matters

ICH E6(R3) uses the term “essential records” for records that permit evaluation of trial conduct and the reliability of results. These records may be held by the investigator, sponsor, or service providers, but responsibility for each record should remain explicit even when systems and activities are distributed. This matters for participant protection, data integrity, and inspection readiness.

For companies operating in Nigeria and across Africa, documentation quality also influences how clinical programmes are perceived by ethics committees, regulators, sponsors, and vendors. Clear records support better oversight, reduce avoidable rework, and make the trial easier to monitor and audit.

Begin during feasibility and start-up

Documentation should begin before the first participant is enrolled. Feasibility records should show how the site’s population, staff, facilities, competing studies, laboratory capacity, and recruitment estimate were assessed. Selection decisions should be traceable to evidence, including identified risks and the mitigations required to address them.

Start-up documentation should include the approved protocol and amendments, investigator brochure or relevant product information, informed-consent materials, ethics and regulatory correspondence, contracts, insurance or indemnity where applicable, investigator qualifications, financial disclosures where required, laboratory documentation, and investigational-product instructions. In Nigeria, NAFDAC’s clinical trial guidance identifies many of these as core submission documents.

Control versions and approvals

A document is not controlled merely because it has a date in its filename. The document system should identify the title, unique identifier, version, effective date, author, reviewer, approver, and change history. Distribution controls should prevent obsolete consent forms, protocols, recruitment materials, or manuals from remaining in use.

Amendments require an impact assessment. The team should determine which approvals, translations, training, system changes, vendor updates, participant re-consent, or data changes are required before implementation. In urgent cases where immediate hazard removal is necessary, the action should still be documented fully and handled under the applicable requirements.

Document conduct as it happens

Source records should capture relevant observations and actions contemporaneously and support the data reported to the sponsor. Corrections should preserve the original information, identify who made the change and when, and explain the reason when it is not apparent. The protocol should define the source of key data, especially when information flows from electronic health records, devices, laboratories, participant reports, or external providers.

High-value records during conduct include consent evidence, eligibility confirmation, visit and procedure records, delegation and training updates, investigational-product accountability, temperature and equipment logs, safety reports, protocol deviations, monitoring outputs, data-query resolution, and important correspondence. Good records explain decisions, not merely confirm that a discussion took place.

Keep sponsor, site, and vendor records aligned

The trial master file and investigator-site file are related evidence sets, not independent archives. A filing plan should state which party holds the authoritative record and how missing, superseded, or transferred records are managed. Periodic reconciliation should cover approvals, safety communications, training, monitoring, deviations, investigational product, vendors, and correspondence.

Monitoring should focus on important errors and omissions and ensure that corrections are dated, explained where necessary, and appropriately documented. Documentation gaps should be assessed for their effect on participant protection and data reliability, followed by proportionate corrective and preventive action.

Close and retain the complete story

Close-out should reconcile investigational product, essential records, outstanding data, safety follow-up, deviations, financial and laboratory records, and vendor deliverables. The investigator should know where records will be retained, how long they must remain available under applicable requirements, who controls access, and how the sponsor will be informed before destruction or relocation.

Strong documentation is concise, contemporaneous, attributable, complete, and retrievable. Its purpose is not to create more paper. Its purpose is to preserve reliable evidence of what happened, why it happened, and how the trial team protected participants and the integrity of the study.

MedNova supports clinical development, regulatory consulting, pharmacovigilance, and resource planning for sponsors and investigators who need practical support across feasibility, study start-up, conduct, and close-out.

References

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E6(R3): Guideline for good clinical practice. Published January 6, 2025. Accessed July 18, 2026. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
2. National Agency for Food and Drug Administration and Control. Guidelines for clinical trial application in Nigeria 2024. Effective November 19, 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/Clinical_Guidelines_2024/Guidelines-for-Clinical-Trial-Application-in-Nigeria.pdf
3. National Agency for Food and Drug Administration and Control. Guidelines for clinical trial protocol development. Effective September 5, 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/Clinical_Guidelines_2024/Guidelines-For-Clinical-Trial-Protocol-Development.pdf